Migraine Headaches: A Historical Prospective, a Glimpse into the Future, and Migraine Epidemiology

Disease-a-Month

Volumn 52, Issue 10, 2006, Pages 367-384

  Unger, Jeff ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDES; BENZOPYRANS; CALCITONIN GENE-RELATED PEPTIDE; DRUG THERAPY, COMBINATION; ERGOTAMINE; HUMANS; INCIDENCE; INDANS; MIGRAINE DISORDERS; PIPERAZINES; PREVALENCE; PROSPECTIVE STUDIES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; SPIRO COMPOUNDS; SUMATRIPTAN; TREATMENT OUTCOME; UNITED STATES; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS; WORLD HEALTH;

EID: 33845211512     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2006.09.002     Document Type: Article

References (61)

1. Edmeads J. The treatment of headache: a historical perspective. In: Gallagher R.M. (Ed). Therapy for headache (1990), Marcel Dekker, New York 1-8
2. Alvarez W.C. Was there sick headache in 3000 BC?. Gastroenterology 5 (1945) 524
3. Lance J.W. Mechanisms and management of headache. 4th edition (1982), Butterworth Scientific, London
4. Rosner F. Headache in the writings of Moses, Maimonides and other Hebrew sages. Headache 33 (1993) 315-319
5. Silberstein S.D., Lipton R.B., and Goadsby P.J. Historical introduction. Headache in clinical practice (1998), Martin Dunitz, London 2
6. Critchley M. Migraine: from Cappodocia to Queen Square. In: Smith R. (Ed). Background to migraine (1967), Heinemann, London 28-38
7. Pearce J.M.S. The headaches of Thomas Jefferson. Cephalalgia 23 (2003) 472-473
8. Chestnutt M. Mary Chestnutt's Civil War (1981), Yale University Press, New Haven
9. King S. Firestarter (1980), Viking Press, New York
10. Graham J.R., and Wolff H.G. Mechanisms of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 39 (1938) 737-763
11. Silberstein S.D. The pharmacology of ergotamine and dihydroergotamine. Headache 37 (1997) S15-S25
12. Welch K.M.A., Nagesh V., Aurora S.K., et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?. Headache 41 (2001) 629-637
13. Anthony M., Hinterberger H., and Lance J.W. Plasma serotonin in migraine and stress. Arch Neurol 16 (1967) 544-552
14. Humphrey P.P.A., Perren M.J., Feniuk W., et al. The pharmacology of the novel 5-HT1-like receptor agonist GR43175. Cephalalgia 9 Suppl 9 (1989) 23-33
15. Humphrey P.P.A., Feniuk W., Marriott A.S., et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur J Neurol 31 (1991) 282-290
16. Perrin V.L., Farkkila M., Goasguen J., et al. Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalgia 9 (1989) 63-72
17. Cady R.K., Wendt J.K., Kirchner J.R., et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265 (1991) 2831-2835
18. Unger J., Cady R.K., and Farmer-Cady K. Migraine headaches, part 2: treatment options. The Female Patient 28 (2003) 1-8
19. Goadsby P.J., Lipton R.B., and Ferrari M.D. Migraine: current understanding and treatment. N Engl J Med 346 (2002) 257-270
20. Ferrari M.D., and Saxena P.R. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 14 (1993) 129-133
21. Goadsby P.J. The pharmacology of headache. Prog Neurobiol 62 (2000) 509-525
22. Mitsikostas D.D., Sanches del Rio M., Moskowits M.A., et al. Both 5-HT1B and 5 HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol 369 (1999) 271-277
23. Goadsby P.J., and Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes see in humans and cats. Ann Neurol 33 (1993) 48-56
24. Storer R.J., Akerman S., and Goadsby P.J. Calcitonin gene-related peptide (CGRP) receptor antagonist modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142 (2004) 1171-1181
25. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 24 (2004) 611-622
26. Tvedskov J.F., Iversen H.K., and Olesen J. A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalgia 24 (2004) 875-882
27. Villalon C.M., Centurion D., Valdivia L.F., et al. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc 45 (2002) 199-210
28. Den Boer M.O., Heiligers J.P., and Saxena P.R. Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT 1-like receptors. Br J Pharmacol 123 (1998) 1561-1570
29. Kapoor K., Willems W., Maassen VanDenBrink A., et al. Assessment of anti-migraine potential of a novel alpha-adrenoceptor agonist S19014: effects on porcine carotid and regional haemodynamics and human coronary artery. Cephalagia 24 (2004) 425-438
30. Breslau N., Chilcoat H., and Andreski P. Further evidence on the link between migraine and neuroticism. Neurology 47 (1996) 663-667
31. Rozen T.D., Swanson J.W., Stang P.E., et al. Incidence of medically recognized migraine: a 1989-1990 study in Olmsted County, Minnesota. Headache 40 (2000) 216-223
32. Cady RK, Weidman E, Unger J, et al. Pediatric migraine. Available at: www.primarycarenet.org/cme/CME11.CFM. Accessed February 11, 2005.
33. Scherer A.I., Stewart W.F., and Lipton R.B. 1999. Migaine and headache: a meta-analytic approach. In: Crombie I. (Ed). Epidemiology of pain (1999), IASP Press, Seattle (WA) 159-170
34. Lavados P.M., and Tehnamm E. Epidemiology of migraine headache in Santiago, Chile: a prevalence study. Cephalalgia 17 (1997) 770-777
35. Rasmussen B.K., and Olesen J. Epidemiology of migraine and tension-type headache. Curr Opin Neurol 7 (1994) 264-271
36. Rasmussen B.K. Epidemiology of migraine. Biomed Pharmacother 49 (1995) 452-455
37. Lipton R.B., Silberstein S.D., and Stewart W.F. An update on the epidemiology of migraine. Headache 34 (1994) 319-328
38. Sakai F., and Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 17 (1997) 15-22
39. Sheffield R.E. Migraine prevalence: a literature review. Headache 38 (1998) 595-601
40. Sheftell F.D., and Tepper S.J. New paradigms in the recognition and acute treatment of migraine. Headache 42 (2002) 58-69
41. Lipton R.B., Stewart W.F., Reed M., et al. Migraine's impact today burden of illness, patterns of care. Postgrad Med 109 (2001) 38-45
42. Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology 1996a;16:231-8.
43. Headache disorders and public health (2000), World Health Organization, Geneva, Switzerland
44. Clarke C.E., MacMillan L., Sondhi S., et al. Economic and social impact of migraine. Q J Med 89 (1996) 77-84
45. Stewart W.F., Lipton R.B., Celentano D.D., et al. Prevalence of migraine headache in the United States: relation to age, income, race and other sociodemographic factors. JAMA 267 (1992) 64-69
46. Vinson D.R. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med 39 (2002) 215-222
47. Stang P.E., Crown W.H., Biz R., et al. The family impact and costs of migraine. Am J Manag Care 10 (2004) 313-320
48. Edmeads J., and Mackell J.A. The economic impact of migraine: an analysis of direct and indirect costs. Headache 42 (2002) 501-509
49. Hu X.H., Markson L.E., Lipton R.B., et al. Burdon of migraine in the United States disability and economics costs. Arch Intern Med 159 (1999) 813-818
50. Osterhaus J.T., Gutterman D.L., and Plachetka J.R. Health care resource and lost labor: cost of migraine headache in the United States. Pharmacoeconomics 2 (1992) 67-76
51. Hu X.H., Markson L.E., Lipton R.B., et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 159 (1999) 813-818
52. Lipton R.B., Stewart W.F., and von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology 48 Suppl 3 (1997) S4-S9
53. Scher A., Stewart W., Libertman J., et al. Prevalence of frequent headache in a population sample. Headache 38 (1998) 497-596
54. Mitsikostas D.D., and Thomas A.M. Comorbidity of headache and depressive disorders. Cephalalgia 19 (1999) 211-217
55. Pesa J., and Lage M.J. The medical costs of migraine and comorbid anxiety and depression. Headache 44 (2004) 562-570
56. Evers S., Suhr B., Bauer B., et al. A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J Neurol 246 (1999) 802-809
57. Silberstein S.D., and Silberstein J.R. Chronic daily headache: long-term prognosis following inpatient treatment with repetitive IV DHE. Headache 32 (1992) 439-445
58. Unger J. The challenge of managing chronic pain in primary care: what critical historical clues are we missing. [editorial]. The Female Patient 29 (2004) 8-9
59. Katsarava Z., Muessig M., Dzagnidze A., et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 25 (2005) 12-15
60. Fritsche G., Eberl A., Katsarava Z., et al. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 45 (2001) 229-235
61. Lipton R.B., Diamond S., Reed M., et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41 (2001) 638-645